Aurobindo Pharma inches up as its arm receives EIR for Raleigh plant
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Aurobindo Pharma is currently trading at Rs. 522.00, up by 1.50 points or 0.29% from its previous closing of Rs. 520.50 on the BSE.
The scrip opened at Rs. 518.05 and has touched a high and low of Rs. 529.45 and Rs. 516.60 respectively. So far 24603 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 751.45 on 04-Oct-2021 and a 52 week low of Rs. 503.40 on 20-Jun-2022.
Last one week high and low of the scrip stood at Rs. 539.10 and Rs. 516.60 respectively. The current market cap of the company is Rs. 30521.54 crore.
The promoters holding in the company stood at 51.83%, while Institutions and Non-Institutions held 38.01% and 10.15% respectively.
Aurobindo Pharma’s wholly owned step-down subsidiary -- Aurolife Pharma LLC has received an establishment inspection report (EIR) for its plant situated at Raleigh, North Carolina, USA , mentioning the inspection a voluntary action initiated (VAI) from the United States Food and Drug Administration (US FDA) and with this, the USFDA pre-approval inspection and GMP inspection are concluded.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
